Serina Therapeutics, Inc. SER
Set alert
1.94 USD +0.05 +2.65%
At close · Oct 30
1.95 +0.01 +0.52%
After hours · Oct 30, 7:23 PM ET
1.69 Day range 2.50
1.28 52-week range 5.00
- YTD
- +1.57%
- 1 year
- -59.50%
- Open
- 1.47
- Prev close
- 1.89
- Mkt cap
- 49.28M
- Vol
- 155.11K
- Avg vol
- 67.75K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.69
- High
- 2.50
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 1.96
- Inst. own
- 3.37%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.80
- 200-d avg
- 8.47
- 1y target
- 0.00
2Y chart
Signals (109)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 5 days ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| RSI: Overbought | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 19, 2026 | 7 months ago |
| RSI: Oversold | Mar 18, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 27, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| RSI: Oversold | Nov 7, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 24, 2025 | 1 year ago |
| SMA: Bullish | Oct 24, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 25, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| SMA: Bearish | Sep 5, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 21, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 19, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| SMA: Bullish | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 27, 2025 | 1 year ago |
| SMA: Bullish | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 30, 2025 | 1 year ago |
| MACD: Sell Signal | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 26, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 18, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 2, 2025 | 1 year ago |
| RSI: Oversold | Nov 25, 2024 | 1 year ago |
| RSI: Oversold | Nov 21, 2024 | 1 year ago |
Key statistics
- Market cap
- 50.72M
- Enterprise value
- 61.58M
- Trailing P/E
- 33.75
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 16.07
- Price / book
- 0.00
- EPS (TTM)
- 0.16
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -232.86%
- Revenue (TTM)
- 3.16M
- Revenue growth
- -53.10%
- Free cash flow
- -7.45M
- Total cash
- 3.19M
- Total debt
- 11.47M
- Return on equity
- 0.00%
- Shares outstanding
- 9.39M
- Short % of float
- 0.67%
- 50-day average
- 5.80
- 200-day average
- 8.47
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SER Revenue — quarterly 0
SER Net income — quarterly -6.36M
SER EPS — quarterly -0.55
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- serinatherapeutics.com
News
- Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance
- Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2
- Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY
- Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease
- BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8
- Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease
- Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders
- Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027
- Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on SER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Dec 16, 2024 | 67,243 |
| JUVENESCENCE LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Mar 13, 2023 | 16,447,500 |
| MINTZ STEVEN MICHAEL | Director | Purchase | Sep 11, 2024 | 0 |
| WEST MICHAEL D | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 9, 2023 | 41,982 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 0.96% | 85,219 | 460.18K | Sep 29, 2024 |
| Waverly Advisors, LLC | 0.76% | 67,492 | 364.46K | Sep 29, 2024 |
| Vanguard Group Inc | 0.50% | 44,500 | 240.30K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.27% | 24,026 | 129.74K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.25% | 22,434 | 121.14K | Sep 29, 2024 |
| Millennium Management Llc | 0.22% | 19,256 | 103.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.36% | 31,799 | 171.71K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 15,593 | 84.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.14% | 12,333 | 66.60K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.09% | 7,900 | 42.66K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 3,720 | 20.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 2,592 | 14.00K | Oct 30, 2024 |